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nderstanding gene expression control requires deﬁning
the molecular and cellular basis of mRNA turnover.
We have previously shown that the human decapping
factors hDcp2 and hDcp1a are concentrated in speciﬁc
cytoplasmic structures. Here, we show that hCcr4, hDcp1b,
hLsm, and rck/p54 proteins related to 5
 
 
 
–3
 
 
 
 mRNA decay
also localize to these structures, whereas DcpS, which is
involved in cap nucleotide catabolism, is nuclear. Functional
analysis using ﬂuorescence resonance energy transfer
revealed that hDcp1a and hDcp2 interact in vivo in these
U
 
structures that were shown to differ from the previously
described stress granules. Our data indicate that these new
structures are dynamic, as they disappear when mRNA break-
down is abolished by treatment with inhibitors. Accumulation
of poly(A)
 
 
 
 RNA in these structures, after RNAi-mediated
inactivation of the Xrn1 exonuclease, demonstrates that they
represent active mRNA decay sites. The occurrence of 5
 
 
 
–3
 
 
 
mRNA decay in speciﬁc subcellular locations in human
cells suggests that the cytoplasm of eukaryotic cells may be
more organized than previously anticipated.
 
Introduction
 
mRNA degradation plays a key role in the regulation of
gene expression by counterbalancing the effects of transcrip-
tion. Analyses, mostly performed in yeast, have revealed five
different exonucleolytic pathways leading to the destruction
of eukaryotic mRNA. In the 5
 
 
 
–3
 
 
 
 mRNA decay pathway,
shortening of the poly(A) tail is followed by cleavage of the
mRNA cap, exposing the mRNA body to the 5
 
 
 
–3
 
 
 
 exonu-
clease Xrn1 (Caponigro and Parker, 1996). The 5
 
 
 
–3
 
 
 
 path-
way appears to be the major route for mRNA degradation
in yeast cells, and it is regulated by controlling the rates
of deadenylation and modulating cap cleavage efficiency
(Caponigro and Parker, 1996). Likewise, the nonsense-
mediated decay (NMD) pathway involves decapping followed
by 5
 
 
 
–3
 
 
 
 digestion of the mRNA. However, during NMD,
these steps are specifically induced by the recognition of a
premature stop codon present in mRNAs (Czaplinski et al.,
1999; Maquat and Carmichael, 2001). The three other
known eukaryotic mRNA turnover pathways, 3
 
 
 
–5
 
 
 
 decay,
nonstop decay (NSD), and 3
 
 
 
–5
 
 
 
 NMD, rely on the activity
of the exosome, a multisubunit complex endowed with 3
 
 
 
–5
 
 
 
exonuclease activity (Mitchell and Tollervey, 2000; Butler,
2002). 3
 
 
 
–5
 
 
 
 decay acts on a fraction of the mRNAs lacking
a poly(A) tail, whereas NSD targets mRNAs missing a
proper stop codon. Finally, although the majority of mRNAs
containing a premature nonsense codon are degraded by
the NMD, a minority appears to be degraded by the 3
 
 
 
–5
 
 
 
NMD pathway (Lejeune et al., 2003; Mitchell and Tollervey,
2003; Takahashi et al., 2003). Thus, NMD, NSD, and 3
 
 
 
–5
 
 
 
NMD allow the removal of aberrant mRNAs and unspliced
pre-mRNAs in the cytoplasm that could be deleterious to
the cell (He et al., 1993; Frischmeyer et al., 2002; van Hoof
et al., 2002). In addition to these exonucleolytic processes,
several groups have reported endonucleolytic inactivation of
specific mRNAs such as human transferrin or IGF-II mRNAs
(Binder et al., 1994; van Dijk et al., 2001). Given the number
and complexity of the pathways implicated in mRNA
degradation, their relative contribution to global mRNA
degradation in human cells remains to be established.
In eukaryotes, the majority of the mRNA degradation
process is thought to occur in the cytoplasm after translation
of the corresponding RNA molecules. However, degradation
of mRNAs and pre-mRNAs also occurs to some extent in
the nucleus. Thus, the 3
 
 
 
–5
 
 
 
 mRNA turnover pathway is
implicated in the decay of pre-mRNAs in yeast nuclei
(Bousquet-Antonelli et al., 2000). Similarly, the cellular
location where the NMD process occurs has been the focus of
numerous studies. Indeed, although NMD was shown to
be cytoplasmic in yeast, it was found associated with the
nucleus in metazoan cells (Ishigaki et al., 2001). However,
this process also requires active translation to promote the
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recognition of premature stop codon. Translation in
metazoan cell nuclei has been reported (Iborra et al.,
2001) but recent evidences suggested that this should be
taken with caution (Bohnsack et al., 2002; Dahlberg et
al., 2003; Nathanson et al., 2003). Therefore, it is cur-
rently believed that NMD occurs during a pioneering
round of translation once the newly synthesized mRNAs
reach the cytoplasm after export through the nuclear pore
complex, thus, being closely associated with the nucleus
(Ishigaki et al., 2001). Newly exported mRNA substrates
for NMD are recognized through their association with
the nuclear cap-binding complex that transits with them
from the nucleus to the cytoplasm (Visa et al., 1996).
They are also punctuated with exon junction complexes
that mark the location of excised introns, thus, playing an
important role in the recognition of premature stop
codons (Le Hir et al., 2001). Another level of complexity
in the degradation of mRNAs arises because the distribu-
tion of some mRNAs is not uniform in the cytoplasm (St
Johnston, 1995). However, it is currently unknown how
this parameter affects mRNA degradation. Thus, overall,
the cellular organization of the mRNA degradation pro-
cess remains to be analyzed.
Although several pathways for mRNA degradation have
been observed and described in human cells (Couttet et
al., 1997; Chen et al., 2001), the factors involved in these
processes and their regulation have remained poorly char-
acterized until recently. Several human factors implicated
in mRNA decay have been identified based on their ho-
mology to yeast factors. This includes proteins involved in
the 5
 
 
 
–3
 
 
 
 pathway, such as the hDcp2 and hDcp1a factors
involved in cap cleavage (Lykke-Andersen, 2002; van Dijk
et al., 2002; Wang et al., 2002), as well as proteins in-
volved in the 3
 
 
 
–5
 
 
 
 pathway, such as subunits of the hu-
man exosome (Allmang et al., 1999; Raijmakers et al.,
2003). Interestingly, characterization of these proteins re-
vealed that they have activities similar to those of their
yeast counterparts. While characterizing the human de-
capping enzyme, we demonstrated that the hDcp1a and
hDcp2 proteins colocalize in new cytoplasmic structures
(van Dijk et al., 2002). Lsm proteins and Xrn1, which are
also involved in 5
 
 
 
–3
 
 
 
 mRNA decay and/or in NMD,
were found also in these structures in human cells (Ingel-
finger et al., 2002), while related structures where subse-
quently observed in yeast (Sheth and Parker, 2003).
Human Dcp-containing bodies were subsequently identi-
fied to structures (GW bodies) containing the GW182
mRNA-binding protein of unknown function (Eystathioy
et al., 2002, 2003). These intriguing observations led us
to ask the following questions: (a) are other mRNA degra-
dation factors localized in the same structures? (b) Are
these structures identical or similar to previously de-
scribed cytoplasmic granules? (c) Do these structures rep-
resent storage sites for mRNA decay factors or do they
represent sites of active mRNA degradation? We have now
addressed these issues, and the results of the experiments
described in the following section indicate that these new
dynamic structures present in the cytoplasm of human
cells represent sites of active mRNA degradation.
 
Results
 
Additional factors linked to mRNA decay localize 
to cytoplasmic foci
 
We showed previously that hDcp1a and hDcp2, involved in
the 5
 
 
 
–3
 
 
 
 mRNA decay pathway, colocalize in cytoplasmic
foci (van Dijk et al., 2002). These structures, which are
known as GW182- or Dcp-containing bodies, could repre-
sent storage sites for these factors or active sites of mRNA
decay. In the latter case, we would anticipate that all factors
involved in the same mRNA degradation pathway would
also localize in these structures, whereas if they represent
storage sites, only factors in excess would be expected to con-
centrate there. To discriminate between these possibilities,
we decided to identify additional human factors with simi-
larity to yeast proteins involved in mRNA decay and to de-
termine their localization through the use of GFP reporter
fusions. Because the Dcp proteins are known to be involved
in the 5
 
 
 
–3
 
 
 
 mRNA decay pathway, we selected factors in-
volved in this process. Thus, we used a cDNA encoding for
a second human protein related to yeast Dcp1, which has
been named hDcp1b (Lykke-Andersen, 2002; van Dijk et
al., 2002). A group of seven proteins of the Sm family,
Lsm1–7, has been shown to interact with the 5
 
 
 
–3
 
 
 
 exonu-
clease Xrn1 and to be required for mRNA decapping in
yeast (Bouveret et al., 2000; Tharun et al., 2000). We se-
lected hLsm3 and hLsm4, which belong to the cytoplasmic
complex involved in 5
 
 
 
–3
 
 
 
 mRNA decay but also associate
with the nuclear U6 snRNP as part of another Lsm protein
complex (Bouveret et al., 2000), and hLsm1, which is spe-
cific for the cytoplasmic complex, for our work, as the corre-
sponding cDNAs were already available (Salgado-Garrido et
al., 1999). We also obtained a published cDNA encoding
the human rck/p54 protooncogene (Lu and Yunis, 1992;
Akao et al., 1995). This protein, containing a putative RNA
helicase domain, is homologous to yeast Dhh1p that has
been shown to interact with yDcp1 and to stimulate decap-
ping in vitro (Coller et al., 2001; Fischer and Weis, 2002).
rck/p54 has been proposed to play a role in translation initi-
ation by restructuring some mRNAs (Akao et al., 2003), and
Xp54, the 
 
Xenopus laevis
 
 homologue of rck/p54, was pro-
posed to be a shuttling protein that associates with nascent
mRNA in the nucleus and accompanies it to the cytoplasm
to control translation (Minshall et al., 2001; Smillie and
Sommerville, 2002). Decapping of the mRNA in the 5
 
 
 
–3
 
 
 
pathway requires prior deadenylation of the mRNA sub-
strate to generate an oligo(A)-containing species, therefore,
we also included hCcr4 in our analysis. Indeed, hCcr4 is ho-
mologous to one of the two subunits of the yeast deaden-
ylase and has been shown likewise to possess 3
 
 
 
 exonuclease
activity in vitro (Chen et al., 2002). Finally, we also analyzed
the localization of DcpS, a protein required for cap nucle-
otide breakdown after mRNA degradation in both the 5
 
 
 
–3
 
 
 
and the 3
 
 
 
–5
 
 
 
 pathways (Wang and Kiledjian, 2001; Liu et
al., 2002; van Dijk et al., 2003). Thus, DcpS served as a
control for a general factor related to overall mRNA decay.
The coding sequences of these various factors were in-
serted downstream of a CMV promoter and the GFP coding
sequence of a mammalian expression vector. Sequencing of 
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the resulting clones confirmed that the coding sequences
were in-frame with the GFP coding sequence and ascer-
tained the absence of unwanted mutations. These plasmids
were introduced into HEK293 human embryonic kidney
cells by transient transfection, and localization of the GFP-
tagged proteins was assessed by microscopic observation of
cells fixed 48 h after transfection and counterstaining with
propidium iodide to reveal the location of nuclei. The GFP–
hDcp1b fusion was found only in the cytoplasm, where it
was nearly exclusively concentrated in bright foci (Fig. 1 A).
hLsm1 was also mostly cytoplasmic. It was also enriched in
foci even though a diffuse staining was also detected (Fig. 1
B). hLsm3 (and hLsm4; unpublished data) was more homo-
geneously distributed, which is consistent with its presence
in two Lsm complexes, one being cytoplasmic and the sec-
ond being nuclear. Nevertheless, a fraction was also enriched
in cytoplasmic foci (Fig. 1 C). These results obtained for
hLsm1, hLsm3, and hLsm4 are consistent with the localiza-
tion data for endogenous or tagged hLsm proteins reported
while this work was in progress (Ingelfinger et al., 2002;
Eystathioy et al., 2003). rck/p54 also displayed a general dif-
fuse staining with accumulation in a discrete number of cy-
toplasmic foci (Fig. 1 D). Interestingly, hCcr4 was exclu-
sively cytoplasmic with several bright foci detectable over a
more general diffuse staining (Fig. 1 E). The absence of
hCcr4 from the nucleus is particularly surprising, as this fac-
tor was also proposed to play a role in transcription (Albert
et al., 2000). Finally, the GFP–DcpS fusion was found to be
nuclear (Fig. 1 F), whereas GFP alone was homogenously
distributed in the cytoplasm of transfected cells in addition
to some nuclear staining (not depicted). Specific staining
was further demonstrated by the absence of cytoplasmic foci
staining with GFP fused to Snu30 or some hDcp1a mutant
(unpublished data). The latter results demonstrate that a cy-
toplasmic distribution with bright foci is not a general phe-
nomenon but rather reflects the specific distribution in-
duced by the passenger protein fused to GFP. We conclude
from this analysis that the factors implicated in 5
 
 
 
–3
 
 
 
 degra-
dation tested are all enriched in specific foci in the cyto-
plasm of human cells.
 
5
 
 
 
–3
 
 
 
 mRNA decay factors colocalize in 
hDcp1a-containing bodies
 
Our observations raised the possibility that all factors accu-
mulating in cytoplasmic foci colocalize in a unique set of
structures. To test this hypothesis, we transiently transfected
HEK293 cells with GFP fusions and assayed simultaneously
for the localization of endogenous hDcp1a by indirect im-
munofluorescence using a rabbit serum (van Dijk et al.,
2002) and anti–rabbit IgG coupled to Cy5 as a secondary
antibody. Thus, overlap of the Cy5 and GFP signals de-
tected by confocal microscopy would reveal the presence of
the factors in the same structures. The results demonstrate
that hDcp1b (Fig. 2 A), hLsm1 (Fig. 2 B), hLsm3 (Fig. 2
C), rck/p54 (Fig. 2 D), and hCcr4 (Fig. 2 E) all colocalize
with structures enriched in hDcp1a (Fig. 2, arrowheads).
Overall, these results demonstrated that all the factors in-
volved in 5
 
 
 
–3
 
 
 
 mRNA tested accumulate in a single type of
cytoplasmic structure even though they show slightly differ-
ent distribution patterns, with some giving in addition dif-
fuse signals in the cytoplasm and/or the nucleus, whereas
others were nearly exclusively present in these structures
(Fig. 1 A, hDcp1b). These small differences may be attrib-
uted to different protein levels and/or to different kinetics of
interaction of these proteins with hDcp1a-containing bod-
ies. The specificity of these colocalization experiments is fur-
ther demonstrated by the observation that factors not specif-
Figure 1. Distribution of various mRNA decay factors in human 
cells. Localization of GFP-hDcp1b (A), GFP-hLsm1 (B), GFP-hLsm3 
(C), GFP-rck/p54 (D), GFP-hCcr4 (E), and GFP-DcpS (F). Left panels 
show GFP signal, middle panels show staining of the nucleus with 
propidium iodide, and right panels show overlays of the two signals. 
Different magnifications were used for the various panels to enhance 
visibility of important features. Some typical foci are indicated 
by arrowheads. 
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ically involved in the 5
 
 
 
–3
 
 
 
 pathway (Fig. 1 F, DcpS) or
other cytoplasmic factors (see previous section) do not accu-
mulate at the same location. Thus, these data are consistent
with these foci representing sites of mRNA decay, although
they do not formally exclude the “storage” hypothesis.
 
hDcp1a-containing bodies are not stress granules
 
Given the accumulation of factors involved in 5
 
 
 
–3
 
 
 
 mRNA
decay in a unique structure, we asked whether or not these
could correspond to previously described bodies. Survey of
the bibliography shows that stress granules have a very simi-
lar distribution. Stress granules are cytoplasmic structures
present in human cells that are related to RNA metabolism
and that are induced upon oxidative stress (e.g., treatment
with arsenite; Kedersha and Anderson, 2002). To test if the
structure containing mRNA decay factors could be stress
granules, HEK293 cells were treated with 0.5 mM sodium
arsenite and stained by indirect immunofluorescence with
anti-hDcp1a rabbit serum and a known marker of stress
granules, namely anti–TIA-1 monoclonal antibodies (Fig. 3).
TIA-1 was mainly nuclear before treatment with sodium ar-
senite (Fig. 3 A, middle), which is consistent with its role in
alternative splicing regulation (Förch et al., 2000), but accu-
mulated in cytoplasmic stress granules after arsenite treat-
ment as described previously (Fig. 3 B, middle; Kedersha et
al., 2002). In contrast, sodium arsenite did not affect hDcp1a
distribution (Fig. 3 B). Furthermore, an overlay of the
hDcp1a and TIA-1 signals demonstrates that the great ma-
jority of these two proteins do not colocalize, even if both
structures were closely localized in rare cases (Fig. 3 B). Thus,
we conclude that hDcp1a-containing bodies are different
from stress granules, at least under the conditions tested.
 
hDcp1a and hDcp2 interact in cytoplasmic foci
 
Analysis of yeast deletion mutants has demonstrated that
mRNA decapping in vivo requires the simultaneous presence
of the Dcp1 and Dcp2 proteins even though Dcp2 is catalyt-
ically active on its own in vitro (Beelman et al., 1996; Dunck-
ley and Parker, 1999; van Dijk et al., 2002). Various analyses
including two-hybrid tests, activity assays, and biochemical
purifications have shown that Dcp1 and Dcp2 interact
(Dunckley and Parker, 1999; Fromont-Racine et al., 2000;
unpublished data). Similarly, hDcp1a and hDcp2 have been
shown to coimmunoprecipitate (Lykke-Andersen, 2002).
Based on the similarity between the yeast and the human
proteins, we may assume that an interaction between hDcp1a
and hDcp2 is required for their activity. Thus, we performed
fluorescence resonance energy transfer (FRET) measurements
to test whether or not these two proteins interact in vivo. For
these experiments, we used previously described plasmids en-
coding hDcp1a or hDcp2 fused either to CFP or YFP pro-
teins (van Dijk et al., 2002). The fluorescent pairs of CFP
and YFP can serve as donor and acceptor, respectively, for
FRET measurements with a calculated Förster distance (R0)
Figure 2. Colocalization of mRNA decay factors with hDcp1a. 
HEK293 cells were transiently transfected with GFP-hDcp1b (A), 
GFP-hLsm1 (B), GFP-hLsm3 (C), GFP- rck/p54 (D), or GFP-hCcr4 (E) 
and counterstained for hDcp1a. Left panels show GFP signals. 
Middle panels show immunostaining with rabbit anti-hDcp1a 
serum (1:1,000) and Fluorolink Cy5-labeled goat anti–rabbit IgG 
(1:1,000). Right panels show overlays of the two signals with 
arrowheads pointing to colocalizing proteins. Different magnifications 
were used for the various panels.
Figure 3. hDcp1a-containing bodies are not stress granules. 
Permeabilized HEK293 cells were incubated with rabbit anti-hDcp1a 
serum and anti–hTIA-1 mAbs (see Material and methods). (A) Untreated 
cells. (B) Cells treated with 0.5 mM sodium arsenite for 30 min. Left 
panels show the hDcp1a signal, middle panels show the hTIA-1 signal, 
and right panels show overlays of these two signals. Bars, 20  m. 
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of 4.9 nm for unoriented molecules (Patterson et al., 2000).
Owing to the presence of endogenous hDcp proteins in the
cells and the variable expression of the fusion constructs, it is
not possible to demonstrate FRET by using sensitized accep-
tor emission. However, FRET efficiency can be measured by
acceptor photobleaching, which makes use of the quenching
of the donor fluorescence when the excitation energy is trans-
ferred to the acceptor by FRET. After acceptor photobleach-
ing, this quenching no longer occurs and the donor fluores-
cence increases. Quantification of this increase is a reliable
measure of FRET (Miyawaki and Tsien, 2000; Wouters et
al., 2001; Verveer et al., 2002).
We first established controls to measure FRET efficiencies.
As positive control, HEK293 cells were transiently trans-
fected with a plasmid encoding a CFP–YFP fusion. A clear
FRET signal was detected (Fig. 4 A). The average apparent
FRET efficiency over several experiments was 16% for this
positive control (Fig. 4 C). In contrast, in HEK293 cells
cotransfected with two independent vectors encoding CFP
and YFP used as a negative control, the average apparent
FRET efficiency was 
 
 
 
8% (Fig. 4 C). Transiently transfected
HEK293 cells expressing CFP-hDcp1a and YFP-hDcp2
demonstrated a clear FRET signal (Fig. 4 B, bottom left) with
an average positive apparent FRET efficiency of 15% over
several experiments (Fig. 4 C). Control quantification of foci
out of the bleached region revealed no FRET signal (Fig. 4 B,
bottom right) and the corresponding average apparent FRET
efficiency was 0.3% (Fig. 4 C). These data indicate that
hDcp1a and hDcp2 interact in vivo in cytoplasmic foci.
 
Translational inhibitors blocking mRNA decay induce 
a decrease in the number of cytoplasmic foci
 
If structures enriched in mRNA decay factors are actively in-
volved in this process, we should expect them to disappear or
to be reduced under a condition where mRNA decay is in-
hibited. In contrast, if they represent the site of mRNA decay
factor storage, we should expect them to increase in number
or size upon mRNA decay inhibition. Translational inhibi-
tors such as cycloheximide are known to stabilize mRNAs
(for review see Jacobson and Peltz, 1996; Ross, 1995) and
represent a useful tool to discriminate between these two hy-
potheses. Thus, the effect of translation inhibitors on the dis-
tribution of cytoplasmic foci containing mRNA decay factors
was assayed by microscopy to draw a link between mRNA
degradation and presence of these structures. We treated
HEK293 cells stably expressing a GFP–hDcp1a fusion with
cycloheximide at 5 
 
 
 
g/ml, as this has been shown to result in
complete inhibition of protein synthesis in mammalian cells
(Pap and Cooper, 2002). Interestingly, addition of cyclohex-
imide resulted in a near-complete disappearance of the cyto-
plasmic foci (Fig. 5, compare A with B). This effect was rela-
tively rapid with an approximately fivefold reduction in the
number of structures per cell already detectable 15 min after
the addition of cycloheximide (Fig. 5 C). [
 
35
 
S]methionine
incorporation indicated that translation inhibition was es-
sentially complete (
 
 
 
80%) and did not increase (variation
 
 
 
/
 
 
 
3%) after this time point (unpublished data). In contrast,
addition of solvent alone did not affect the average number
of hDcp1a-labeled foci per cell (Fig. 5 C). Western blot anal-
Figure 4. hDcp1a and hDcp2 interact in cytoplasmic foci. 
(A) Example of a FRET experiment where a fusion protein, CFP-YFP, 
was expressed in HEK293 cells as a positive control. A picture of the 
YFP signal was taken after photobleaching of a rectangular sector 
overlapping the cell (outlined in the CFP signal picture, bottom). A 
picture of the CFP signal was taken before (top right) and after (bot-
tom) photobleaching of the YFP. Apparent FRET efficiency (18% for 
this experiment) was calculated as described in Materials and meth-
ods. (B) Example of a FRET experiment where CFP-hDcp1a and 
YFP-hDcp2 were expressed in HEK293 cells. Pictures were taken as 
described in A. Quantification of a foci in the bleached region 
shows an apparent FRET efficiency of 17% for this experiment (bot-
tom left), whereas quantification of a foci out of the bleached region 
shows FRET efficiency of 4% (bottom right). (C) Histogram repre-
senting the average apparent FRET efficiency for the different con-
structions in different experiments. Error bars indicate the standard 
deviation from the independent measurements. 
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ysis demonstrated that the decreased number of foci did not
result from a decreased level of the GFP-tagged protein, as it
was stable for several hours (unpublished data). Thus, these
data demonstrate that cytoplasmic bodies disappear when
translation and, consequently, mRNA decay are inhibited af-
ter treatment of the cells with cycloheximide. Similar results
have been obtained with other translational inhibitors (un-
published data). Overall, these results provide a strong indi-
cation that the hDcp1a-containing bodies are actual sites of
mRNA decay rather than storage sites for mRNA decay fac-
tors. This conclusion is further supported by the disappear-
ance of these structures in mitosis, during which mRNA de-
cay is also abolished (unpublished data). Furthermore, these
data demonstrate the highly dynamic nature of the cytoplas-
mic structures containing 5
 
 
 
–3
 
 
 
 mRNA decay factors.
 
Ongoing transcription is required for body maintenance
 
If cytoplasmic foci are the actual sites of mRNA degrada-
tion, their presence should be dependent on the presence of
substrate mRNAs. To test whether or not this is the case, we
analyzed the number of hDcp1a-labeled foci in cells treated
with the PolII inhibitor actinomycin D (5 
 
 
 
g/ml). Treat-
ment of the cell line HEK293 stably expressing a GFP–
hDcp1a fusion with actinomycin D lead to the near-com-
plete disappearance of hDcp1a-containing bodies (Fig. 6,
compare A with B). Quantitative analysis (Fig. 6 C) revealed
that the actinomycin D effect was slower than that of cyclo-
heximide, suggesting that it could be more indirect (e.g., re-
quiring the near-complete disappearance of all mRNAs).
Again, this effect was not detected in cells treated with sol-
vent alone (Fig. 6 C), and it did not reflect the absence of
the GFP–hDcp1a fusion because Western blot experiments
demonstrated that the fusion protein was present at similar
levels at all time points (not depicted). Thus, we conclude
that ongoing transcription is required for maintenance of
these cytoplasmic foci.
 
Poly(A)
 
 
 
 RNA accumulates in hDcp2-containing 
structures after RNAi-mediated Xrn1 inactivation
 
If structures containing mRNA degradation factors are active
mRNA decay centers, rather than storage sites, they should
contain decay intermediates. However, such intermediates are
difficult to detect due to their extremely short half-lives and
low concentration. Because Xrn1 is the major 5
 
 
 
–3
 
 
 
 exonu-
clease responsible for degradation of mRNA bodies in the 5
 
 
 
–
3
 
 
 
 and NMD pathways, we reasoned that its inactivation
should lead to the accumulation of cognate intermediates.
Thus, inactivating Xrn1 function using RNAi should result in
the accumulation of RNA intermediates in hDcp2-contain-
Figure 5. hDcp1a-containing bodies disappear after treatment 
with cycloheximide. HEK293 cells stably expressing hDcp1a were 
treated with 5  g/ml cycloheximide for 5, 15, 30, and 120 min. 
Six fields randomly chosen were observed per time point, and number 
of foci per cell (covering  170 cells) was counted and reported on a 
histogram. (A) Distribution of hDpc1a at time 0. (B) Distribution of 
hDcp1a after 2 h of treatment. Bars, 20  m. (C) Histogram repre-
senting a time course evolution of the average number of foci. Black 
bars represent untreated cells, gray bars represent treatment with 
DMSO, white bars represent treatment with cycloheximide, and the 
shaded bar represents cells at time 0 before any treatment.
Figure 6. hDcp1a-containing bodies disappear after treatment 
with actinomycin D. HEK293 cells stably expressing hDcp1a were 
treated with 5  g/ml actinomycin D for 2, 4, 8, and 24 h. Six fields 
randomly chosen were observed per time point and number of foci 
per cell was counted and reported on a graph. (A) Distribution of 
hDpc1a at time 0. (B) Distribution of hDcp1a after 24 h of treatment. 
Bars, 10  m. (C) Histogram representing time course evolution of 
the average number of foci. Black bars represent treatment with 
DMSO, white bars represent treatment with actinomycin D, and the 
shaded bar represents cells at time 0 before any treatment. 
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ing structures, if they are involved in mRNA turnover. To test
this possibility, we generated cells stably transfected with a
plasmid governing the expression of shRNAs (Brummelkamp
et al., 2002; Paddison et al., 2002) targeted against Xrn1 (or
as control shRNAs with inactive sequence). These construc-
tions were performed in cells stably expressing a GFP–hDcp2
fusion to allow the detection of the corresponding factor. In
the resulting cells, shRNA expression induced a strong reduc-
tion of the Xrn1 mRNA level that dropped to 20% of its
amount in control cells (Fig. 7 A). To detect mRNA decay in-
termediates, we reasoned that a fraction of the Xrn1 sub-
strates should contain a poly(A) tail because decapping occurs
when an oligo(A) tail is still present on mRNA 3
 
 
 
 ends and
because NMD substrates can be degraded without complete
deadenylation (Couttet and Grange, 2004). Thus, in Xrn1-
depleted cells, poly(A)
 
 
 
 RNAs were detected by FISH using a
fluorescent Cy5-oligod(T)
 
20
 
 probe (Buhler et al., 2002). In-
terestingly, a signal accumulated in discrete cytoplasmic foci
(Fig. 7 B). No cytoplasmic accumulation of poly(A)
 
 
 
 RNAs
was observed in control cells (Fig. 7 B and not depicted), in-
dicating that the poly(A)
 
 
 
 signal present in the foci resulted
from Xrn1 inactivation. Similar results were obtained with a
second FISH protocol (Boehmer et al., 2003), confirming the
validity of this observation (unpublished data). Colocalization
experiments indicated that the site of poly(A)
 
 
 
 RNA foci de-
tected after RNAi-mediated Xrn1 inactivation corresponded
to structures labeled with GFP-hDcp2 (Fig. 7 C). Together,
these results indicate that cytoplasmic sites of mRNA decay
factors accumulation represent active mRNA decay centers
rather than storage structures.
 
Discussion
We previously identified hDcp2 as the catalytic subunit of the
human decapping enzyme and observed, surprisingly, that it
was enriched together with hDcp1a in cytoplasmic foci (van
Dijk et al., 2002). In this paper, we asked if additional factors
were present in these foci, if these foci were identical to some
previously known cytoplasmic structures present in human
cells, and if we could establish a link between these sites and
the location of mRNA decay in human cells.
Our results demonstrate that all factors involved in 5 –3 
mRNA decay tested accumulate at least to some extent in a
unique set of structures despite the fact that these proteins
show a somewhat different overall distribution in cells. These
proteins include factors involved in mRNA deadenylation
(hCcr4), mRNA decapping (hDcp1a, hDcp1b, and hDcp2),
as well as factors required for decapping activation (hLsm
proteins and rck/p54). While this work was in progress,
the colocalization of Lsm1–7 proteins with hDcp1a and/or
hDcp2 in cytoplasmic foci was observed independently (In-
gelfinger et al., 2002; Eystathioy et al., 2003). These foci also
correspond to sites of accumulation of the 5 –3  exonuclease
Xrn1 (Bashkirov et al., 1997; Ingelfinger et al., 2002). This
clustering of 5 –3  mRNA decay factors contrasts with the
nuclear location of DcpS (involved in cap nucleotide break-
down after mRNA decay in both the 3 –5  and 5 –3 
mRNA decay) or with the location of the human exosome,
which appears mostly concentrated in the nucleus and the
nucleolus (Raijmakers et al., 2003). The accumulation of all
factors tested in a single set of structures suggests that they
represent the actual site of mRNA decay rather than storage
sites. Indeed, in the latter case, one may have anticipated that
some factors would be present in excess, and thus stored,
whereas others, limiting for the degradation process, would
not accumulate in the storage compartment. The recent ob-
servation that another RNA binding protein of unknown
function, GW182, also localizes in the same structure in
Hep-2 (Eystathioy et al., 2003) and HEK293 cells (unpub-
lished data) also supports a role for these structure bodies in
RNA metabolism. Further, we note that after the observation
of the peculiar distribution of hDcp1a and hDcp2, a related
observation was made in yeast cells (Sheth and Parker, 2003),
even though in another study a more uniform distribution of
the same proteins was reported (Tharun et al., 2000). The
structures described in yeast contain the Dcp proteins, other
mRNA decay factors, and mRNA decay intermediates (Sheth
Figure 7. poly(A)
  RNA accumulate in hDcp2-containing bodies 
after RNAi-mediated Xrn1 inactivation. (A) Northern blotting analysis 
of Xrn1 expression in control and Xrn1-inactivated cells. GAPDH 
mRNA was used as a loading control. Note that as the shRNA-
expressing construct is stably integrated, reduced mRNA levels are 
expected to translate into corresponding reduced protein levels 
independently of the protein half-life except in the case of feed-back 
control. (B) poly(A)
  RNA detection by FISH in control cells (left) 
and Xrn1-inactivated RNAi cells (right). Arrowheads indicate sites 
of accumulation of poly(A)
  RNAs that may originate from incomplete 
deadenylation before decapping (Daugeron et al., 2001), overflow 
of the mRNA decay machinery resulting from Xrn1 inactivation, 
and/or degradation of NMD substrates. (C) Colocalization of GFP-
hDcp2 and poly(A)
  mRNA accumulation sites. Left panels show 
GFP signal of GFP-hDcp2 fusion, middle panels show Cy5 signal 
corresponding to poly(A)
  RNAs, and right panels show overlay of 
the two signals, with arrowheads indicating colocalization. Bars, 4  m.38 The Journal of Cell Biology | Volume 165, Number 1, 2004
and Parker, 2003). Given the similarity between the factors
involved in mRNA decay in yeast and humans, this observa-
tion reinforces our conclusion that Dcp-containing bodies
containing 5 –3  mRNA decay factors are mRNA degrada-
tion centers. However, these structures are unlikely to be
identical because hCcr4 is present in human bodies, whereas
yeast Ccr4 is not detected in the yeast structures.
The use of translational inhibitors that are known to inhibit
mRNA decay strongly suggests that cytoplasmic foci represent
sites of mRNA decay. Indeed, translational inhibitors induced
the disappearance rather than an enlargement of these struc-
tures. Our observation that two factors required for mRNA
decapping interact in vivo in these foci also supports an active
role for these structures. Further arguments for the functional
nature of these bodies come from their absence from mitotic
cells (unpublished data) or after transcriptional inhibition,
consistent with the proposed absence of mRNA degradation
under these conditions (Ross, 1997). To confirm this possibil-
ity, we inactivated Xrn1 by RNAi treatment to induce accu-
mulation of otherwise undetectable mRNA decay intermedi-
ates. This strategy resulted in the accumulation of poly(A)
 
RNA in specific cytoplasmic foci that coincided with the loca-
tion of the hDcp2 protein. These results indicate definitively
that the cytoplasmic structures concentrating mRNA decay
factors are active mRNA decay centers. Given that factors in-
volved in decapping and 5 –3  exonucleolytic trimming are
also involved in NMD, it is tempting to speculate that this
process occurs at the same location. Consistent with this pos-
sibility, hDcp1a and hDcp1b have been found to interact
with hUpf1 that is involved in NMD (Lykke-Andersen,
2002). Even though our data indicate that 5 –3  mRNA de-
cay and NMD occur in a dedicated subcellular compartment,
there is currently no obvious reason to explain why it should
be so. One can hypothesize that this may serve to enhance the
process through substrate channeling. Alternatively, a dedi-
cated structure may prevent unwanted mRNA degradation in
the cytoplasm. The cellular machinery involved in the target-
ing of the various components of these structures to their cor-
rect location and in the dynamic maintenance of these bodies
remains to be identified. The localization of some individual
factors gives also some interesting feedback information on
their functions. Thus, rck/p54, the homologue of the yeast
Dhh1 helicase, has been proposed to function in initiation of
translation and translational control (Minshall et al., 2001;
Smillie and Sommerville, 2002; Akao et al., 2003). In yeast,
its homologue, Dhh1, interacts with Dcp1 and enhances de-
capping in vitro (Coller et al., 2001; Fischer and Weis, 2002).
We observed that a fraction of rck/p54 localizes in cytoplas-
mic foci. Based on this result and on the homology of rck/p54
with yeast Dhh1, we propose that the protooncogene rck/p54
plays a role in activation of decapping as does the yeast homo-
logue. The cytoplasmic location of hCcr4 is also informative,
as this protein has been implicated in both transcription and
mRNA degradation. The presence of an evolutionarily con-
served nuclease domain (Chen et al., 2002), together with its
accumulation in the cytoplasm and a (near-)complete nuclear
exclusion (see Results), supports its role in mRNA degrada-
tion, even though a function in transcription cannot be ruled
out. The exclusive nuclear localization of DcpS is also of inter-
est. On the one hand, this feature appears evolutionarily con-
served because the DcpS homologue from Schizosaccharomyces
pombe also localizes in the nucleus (Salehi et al., 2002). On
the other hand, we recently demonstrated that DcpS is in-
volved in 7-methyl guanine–containing cap nucleotide break-
down in both the 5 –3  and 3 –5  pathways and hypothesized
that this function might be required to prevent the deleterious
consequences of incorporation of methylated G residues in
RNA and/or DNA (van Dijk et al., 2003). The localization of
DcpS in the nucleus, the main cellular site for transcription
and DNA replication, is fully consistent with this possibility.
An interesting aspect of the cytoplasmic structures involved
in mRNA decay is their dynamic nature. This feature will also
probably be reflected in a heterogeneous composition and
shape that will reflect the kinetic of association of individual
factors with each structure. Thus, this may explain the slight
differences in the number of foci and variation in staining in-
tensities for individual factors. The observation of these new
dynamic cytoplasmic structures raised the question of whether
or not they corresponded to previously described bodies or to
new cellular entities. Our data show clearly that they are not
identical to stress granules even though both are highly dy-
namic and connected to mRNA metabolism. Other cytoplas-
mic structures related to RNA metabolism have been identi-
fied in specific cells, such as polar granules in Caenorhabditis
elegans and Drosophila melanogaster oocytes and germ plasm in
X. laevis oocytes (Micklem, 1995). However, given their re-
stricted tissues distribution, such structures are unlikely to
have a relation to the cytoplasmic mRNA degradation foci
that we observe in human cells. Overall, these observations in-
dicate that the cytoplasm may be more organized than previ-
ously anticipated. Interestingly, during the past years, results
demonstrating that the eukaryotic nucleus is divided in highly
dynamic but functionally distinct compartments have also ac-
cumulated (Lamond and Earnshaw, 1998). Further work will
be necessary to understand the composition of the various cy-
toplasmic structures involved in mRNA metabolism and their
functions in the precise control of gene expression.
Materials and methods
Plasmid constructions
cDNAs encoding hDcp1a or hDcp2 were cloned in peGFP-C2, peCFP-C1,
and peYFP-C1 plasmids (CLONTECH Laboratories, Inc.; van Dijk et al.,
2002). Plasmids harboring cDNAs corresponding to hCcr4 (a gift from L.
Corbo, Centre Léon Bérard, Lyon, France; pBS2308), hDcp1b (pBS2326; IM-
AGE:5296928), hLsm1(pBS1457), hLsm3 (pBS981), hLsm4 (pBS1169), DcpS
(pBS2419; IMAGE:1192708), and rck/p54 (from a rck/p54 expression plas-
mid; a gift from Y. Akao, Gifu International Institute of Biotechnology, Gifu,
Japan) were used to construct GFP fusion in peGFP vectors (CLONTECH
Laboratories, Inc.) using standard techniques (Sambrook et al., 1989). This
procedure yielded the following constructs: GFP-hCCr4 (pBS2560), GFP-
hDcp1b (pBS2408), GFP-hLsm1 (pBS2378), GFP-hLsm3 (pBS2343), GFP-
hLsm4 (pBS2344), GFP-DcpS (pBS2563), and GFP-rck/p54 (pBS2564). The
localization of these GFP fusions was consistent with the known localization
of the cognate endogenous proteins except for hCcr4, p54/rck, hDcp1b, and
DcpS that have not been tested in the absence of suitable antibodies. All
constructs were verified by sequencing. YFP ORF was excised from peYFP-
C1 and cloned in-frame at the COOH terminus of CFP in peCFP-C1 yielding
the peCFP-YFP construct (pBS2559). The pBS2520 plasmid encoding sh-
RNAs targeted against Xrn1 was generated by insertion of oligonucleotides
generating the sequence CGTCATGGCAAGGAGTTACCTTCAAGAGAGG-
TAACTCCTTGCCATGACTTTTTTGGAA (target sequence is in bold) be-
tween the BamHI and HindIII sites of pSilencer hygro™ (Ambion). As nega-
tive control, we used the shRNA encoding plasmid with no similarity to
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RNA isolation and Northern blotting analysis
Total RNA was extracted from 10
7 cells using Tri Reagent (Sigma-Aldrich)
according the manufacturer’s instructions. 50  g of total RNA were electro-
phoresed onto 0.8% agarose/2 M formaldehyde gels and transferred to Hy-
bond-N
  nylon membranes (Amersham Biosciences). After prehybridiza-
tion, blots were sequentially hybridized for 24 h at 50 C to 2   10
6 cpm/ml
of hXrn1 and GAPDH cDNA probes (Multiprime DNA Labeling System;
Amersham Biosciences). ImageQuant software was used for quantification.
Cell culture and transfection
Cell culture conditions were as described previously (van Dijk et al.,
2002). For transient transfection,  3   10
6 HEK293 cells were transfected
with 1  g of plasmid DNA using the Effectene transfection reagent
(QIAGEN). Stable transfections were performed using the same protocol.
Cells were cultured for 2 d without selection agent and selected for 2–3
mo with 400  g/ml G418 and/or 200  g/ml hygromycin (Invitrogen). Cells
were cloned and selected for expression of the fluorescent protein. Cells
were treated with 5  g/ml cycloheximide or actinomycin D dissolved in
DMSO for the time indicated.
Indirect immunofluorescence and GFP localization
HEK293 cells were grown in DME Glutamax (Invitrogen) containing 10%
FCS on clean glass slides to 70% confluence. The cells were washed with
1  PBS and fixed for 20 min in 4% PFA. After several washes, cells were
permeabilized in 0.1% Triton X-100 for 10 min. Then, cells were saturated
for 30 min with 0.2% BSA/1  PBS, and after several washes cells were im-
munostained for 1 h at 37 C with a rabbit anti-hDcp1a serum (1:1,000) or
anti–hTIA-1 mAbs (provided by N. Kedersha, Harvard Medical School,
Boston, MA; 1:1,000). After subsequent washes, cells were incubated 1 h
at 37 C with secondary antibody, Fluorolink Cy5-labeled goat anti–rabbit
IgG (Amersham Biosciences) for anti-hDcp1a serum or goat anti–mouse
IgG FITC conjugated (Sigma-Aldrich) for anti–hTIA-1 antibodies (1:1,000).
The anti-hDcp1a serum used for immunofluorescence revealed specifi-
cally hDcp1a in Western blotting analysis (van Dijk et al., 2002).
For localization of the GFP fusions, cells were fixed and treated as de-
scribed in the previous paragraph and nuclei were stained for 30 min in a
dark chamber with 5  g/ml propidium iodide. For the colocalization
experiments, HEK293 cells were transiently transfected either with GFP-
hCcr4, GFP-hDcp1b, GFP-hLsm1, GFP-hLsm3, or GFP-rck/p54 as described
in Cell culture and transfection. Then, cells were stained by immunofluo-
rescence as described in the previous paragraph.
Preparations were analyzed using a confocal microscope (model RCS
SP2; Leica) on an inverted stand using objectives HC Plan APO OS 100 
oil NA 1.4. Specific excitation of GFP fusions was performed at 488 nm
and collection of emitted light at 500–542 nm. Images were prepared us-
ing Leica software.
Acceptor photobleaching FRET
All data were obtained on a microscope (model RCS SP2; Leica). Samples
were mounted as described in Indirect immunofluorescence and GFP lo-
calization, and images were acquired with objectives HC Plan APO OS
100  oil NA 1.4. Specific excitation of CFP-hDcp1a was performed at 458
nm and collection of emitted light at 495 nm. No emission from YFP-
hDcp2 was observed in CFP channel. Images in the CFP channel were
taken before and after photobleaching using the same sensitivity settings.
YFP fusions were photobleached with full power excitation at 514 nm. Im-
ages of YFP-hDcp2 were taken after photobleaching and no CFP pho-
tobleaching was observed under these conditions. Apparent FRET effi-
ciency was calculated using Leica software and according to the following
equation: Ea   (Ipost-Ipre)/Ipost, where Ipost is the mean amplitude of CFP
signal after YFP photobleaching, and Ipre is the mean amplitude of CFP
signal before YFP photobleaching.
Fluorescent in situ hybridization
Poly(A)
  RNAs were detected as described previously (Buhler et al., 2002).
In brief, cells were grown on coverslips for 48 h, fixed with 4% PFA for 30
min, and permeabilized overnight at 4 C with 70% ethanol. Then, cells
were rehydrated with 2  SSC/50% formamide and hybridization was car-
ried out with 300 ng Cy5 oligod(T) in 15% formamide in a humidified dark
chamber at 37 C for 3 h. After three washes with 2  SSC/50% formamide,
coverslip were mounted and analyzed by confocal microscopy as de-
scribed in Indirect immunofluorescence and GFP localization.
We thank Séraphin laboratory members for critical comments; Dr. N. Ke-
dersha for antibodies; and Dr. Y. Akao and Dr. L. Corbo for the gift of plas-
mids. Microscopy was done in the core facility of the Centre National de la
Recherche Scientifique (CNRS) campus supported by the Institut Fédératif
de Recherche 87 (La plante et son environnement) and the Action de Sou-
tien à la Technologie et la Recherche en Essonne program of the Conseil
Général de l’Essonne with expert assistance from S. Brown and C. Talbot.
This work was funded by La Ligue pour la Recherche contre le Cancer
(Equipe Labelisée), the Research Ministlry (grant ACI-BCMS), and the
CNRS.
Submitted: 2 September 2003
Accepted: 5 March 2004
References
Akao, Y., O. Marukawa, H. Morikawa, K. Nakao, M. Kamei, T. Hachiya, and Y.
Tsujimoto. 1995. The rck/p54 candidate proto-oncogene product is a 54-
kilodalton D-E-A-D box protein differentially expressed in human and
mouse tissues. Cancer Res. 55:3444–3449.
Akao, Y., H. Yoshida, K. Matsumoto, T. Matsui, K. Hogetu, N. Tanaka, and J.
Usukura. 2003. A tumour-associated DEAD-box protein, rck/p54 exhibits
RNA unwinding activity toward c-myc RNAs in vitro. Genes Cells. 8:671–676.
Albert, T.K., M. Lemaire, N.L. van Berkum, R. Gentz, M.A. Collart, and H.T.
Timmers. 2000. Isolation and characterization of human orthologs of yeast
CCR4-NOT complex subunits. Nucleic Acids Res. 28:809–817.
Allmang, C., E. Petfalski, A. Podtelejnikov, M. Mann, D. Tollervey, and P. Mitch-
ell. 1999. The yeast exosome and human PM-Scl are related complexes of
3  → 5  exonucleases. Genes Dev. 13:2148–2158.
Bashkirov, V.I., H. Scherthan, J.A. Solinger, J.M. Buerstedde, and W.D. Heyer.
1997. A mouse cytoplasmic exoribonuclease (mXRN1p) with preference for
G4 tetraplex substrates. J. Cell Biol. 136:761–773.
Beelman, C.A., A. Stevens, G. Caponigro, T.E. LaGrandeur, L. Hatfield, D.M.
Fortner, and R. Parker. 1996. An essential component of the decapping en-
zyme required for normal rates of mRNA turnover. Nature. 382:642–646.
Binder, R., J.A. Horowitz, J.P. Basilion, D.M. Koeller, R.D. Klausner, and J.B.
Harford. 1994. Evidence that the pathway of transferrin receptor mRNA
degradation involves an endonucleolytic cleavage within the 3  UTR and
does not involve poly(A) tail shortening. EMBO J. 13:1969–1980.
Boehmer, T., J. Enninga, S. Dales, G. Blobel, and H. Zhong. 2003. Depletion of a
single nucleoporin, Nup107, prevents the assembly of a subset of nucleopor-
ins into the nuclear pore complex. Proc. Natl. Acad. Sci. USA. 100:981–985.
Bohnsack, M.T., K. Regener, B. Schwappach, R. Saffrich, E. Paraskeva, E. Hart-
mann, and D. Görlich. 2002. Exp5 exports eEF1A via tRNA from nuclei
and synergizes with other transport pathways to confine translation to the
cytoplasm. EMBO J. 21:6205–6215.
Bousquet-Antonelli, C., C. Presutti, and D. Tollervey. 2000. Identification of a
regulated pathway for nuclear pre-mRNA turnover. Cell. 102:765–775.
Bouveret, E., G. Rigaut, A. Shevchenko, M. Wilm, and B. Séraphin. 2000. A Sm-
like protein complex that participates in mRNA degradation. EMBO J. 19:
1661–1671.
Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. A system for stable expres-
sion of short interfering RNAs in mammalian cells. Science. 296:550–553.
Buhler, M., M.F. Wilkinson, and O. Muhlemann. 2002. Intranuclear degradation
of nonsense codon-containing mRNA. EMBO Rep. 3:646–651.
Butler, J.S. 2002. The yin and yang of the exosome. Trends Cell Biol. 12:90–96.
Caponigro, G., and R. Parker. 1996. Mechanisms and control of mRNA turnover
in Saccharomyces cerevisiae. Microbiol. Rev. 60:233–249.
Chen, C.Y., R. Gherzi, S.E. Ong, E.L. Chan, R. Raijmakers, G.J. Pruijn, G. Stoeck-
lin, C. Moroni, M. Mann, and M. Karin. 2001. AU binding proteins recruit
the exosome to degrade ARE-containing mRNAs. Cell. 107:451–464.
Chen, J., Y.C. Chiang, and C.L. Denis. 2002. CCR4, a 3 -5  poly(A) RNA and ss-
DNA exonuclease, is the catalytic component of the cytoplasmic deaden-
ylase. EMBO J. 21:1414–1426.
Coller, J.M., M. Tucker, U. Sheth, M.A. Valencia-Sanchez, and R. Parker. 2001.
The DEAD box helicase, Dhh1p, functions in mRNA decapping and interacts
with both the decapping and deadenylase complexes. RNA. 7:1717–1727.
Couttet, P., and T. Grange. 2004. Premature termination codons enhance mRNA
decapping in human cells. Nucleic Acids Res. 32:488–494.
Couttet, P., M. Fromont-Racine, D. Steel, R. Pictet, and T. Grange. 1997. Mes-
senger RNA deadenylylation precedes decapping in mammalian cells. Proc.
Natl. Acad. Sci. USA. 94:5628–5633.
Czaplinski, K., M.J. Ruiz-Echevarria, C.I. Gonzalez, and S.W. Peltz. 1999. Should
we kill the messenger? The role of the surveillance complex in translation
termination and mRNA turnover. Bioessays. 21:685–696.40 The Journal of Cell Biology | Volume 165, Number 1, 2004
Dahlberg, J.E., E. Lund, and E.B. Goodwin. 2003. Nuclear translation: what is the
evidence? RNA. 9:1–8.
Daugeron, M.C., F. Mauxion, and B. Séraphin. 2001. The yeast POP2 gene en-
codes a nuclease involved in mRNA deadenylation. Nucleic Acids Res. 29:
2448–2455.
Dunckley, T., and R. Parker. 1999. The DCP2 protein is required for mRNA de-
capping in Saccharomyces cerevisiae and contains a functional MutT motif.
EMBO J. 18:5411–5422.
Eystathioy, T., E.K. Chan, S.A. Tenenbaum, J.D. Keene, K. Griffith, and M.J.
Fritzler. 2002. A phosphorylated cytoplasmic autoantigen, GW182, associ-
ates with a unique population of human mRNAs within novel cytoplasmic
speckles. Mol. Biol. Cell. 13:1338–1351.
Eystathioy, T., A. Jakymiw, E.K.L. Chan, B. Séraphin, N. Cougot, and M.J. Fritzler.
2003. The GW182 protein colocalizes with mRNA degradation associated
proteins hDcp1and hLSm4 in cytoplasmic GW bodies. RNA. 9:1171–1173.
Fischer, N., and K. Weis. 2002. The DEAD box protein Dhh1 stimulates the de-
capping enzyme Dcp1. EMBO J. 21:2788–2797.
Förch, P., O. Puig, N. Kedersha, C. Martinez, S. Granneman, B. Séraphin, P.
Anderson, and J. Valcárcel. 2000. The apoptosis-promoting factor TIA-1 is
a regulator of alternative pre-mRNA splicing. Mol. Cell. 6:1089–1098.
Frischmeyer, P.A., A. van Hoof, K. O’Donnell, A.L. Guerrerio, R. Parker, and
H.C. Dietz. 2002. An mRNA surveillance mechanism that eliminates tran-
scripts lacking termination codons. Science. 295:2258–2261.
Fromont-Racine, M., A.E. Mayes, A. Brunet-Simon, J.C. Rain, A. Colley, I. Dix,
L. Decourty, N. Joly, F. Ricard, J.D. Beggs, and P. Legrain. 2000. Genome-
wide protein interaction screens reveal functional networks involving Sm-
like proteins. Yeast. 17:95–110.
He, F., S.W. Peltz, J.L. Donahue, M. Rosbash, and A. Jacobson. 1993. Stabiliza-
tion and ribosome association of unspliced pre-mRNAs in a yeast upf1- mu-
tant. Proc. Natl. Acad. Sci. USA. 90:7034–7038.
Iborra, F.J., D.A. Jackson, and P.R. Cook. 2001. Coupled transcription and trans-
lation within nuclei of mammalian cells. Science. 293:1139–1142.
Ingelfinger, D., D.J. Arndt-Jovin, R. Luhrmann, and T. Achsel. 2002. The human
LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and
Xrnl in distinct cytoplasmic foci. RNA. 8:1489–1501.
Ishigaki, Y., X. Li, G. Serin, and L.E. Maquat. 2001. Evidence for a pioneer round
of mRNA translation: mRNAs subject to nonsense-mediated decay in mam-
malian cells are bound by CBP80 and CBP20. Cell. 106:607–617.
Jacobson, A., and S.W. Peltz. 1996. Interrelationships of the pathways of mRNA
decay and translation in eukaryotic cells. Annu. Rev. Biochem. 65:693–739.
Kedersha, N., and P. Anderson. 2002. Stress granules: sites of mRNA triage that reg-
ulate mRNA stability and translatability. Biochem. Soc. Trans. 30:963–969.
Kedersha, N., S. Chen, N. Gilks, W. Li, I.J. Miller, J. Stahl, and P. Anderson.
2002. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient
preinitiation complexes are core constituents of mammalian stress granules.
Mol. Biol. Cell. 13:195–210.
Lamond, A.I., and W.C. Earnshaw. 1998. Structure and function in the nucleus.
Science. 280:547–553.
Lejeune, F., X. Li, and L.E. Maquat. 2003. Nonsense-mediated mRNA decay in
mammalian cells involves decapping, deadenylating, and exonucleolytic ac-
tivities. Mol. Cell. 12:675–687.
Le Hir, H., D. Gatfield, E. Izaurralde, and M.J. Moore. 2001. The exon-exon
junction complex provides a binding platform for factors involved in mRNA
export and nonsense-mediated mRNA decay. EMBO J. 20:4987–4997.
Liu, H., N.D. Rodgers, X. Jiao, and M. Kiledjian. 2002. The scavenger mRNA de-
capping enzyme DcpS is a member of the HIT family of pyrophosphatases.
EMBO J. 21:4699–4708.
Lu, D., and J.J. Yunis. 1992. Cloning, expression and localization of an RNA heli-
case gene from a human lymphoid cell line with chromosomal breakpoint
11q23.3. Nucleic Acids Res. 20:1967–1972.
Lykke-Andersen, J. 2002. Identification of a human decapping complex associ-
ated with hUpf proteins in nonsense-mediated decay. Mol. Cell. Biol. 22:
8114–8121.
Maquat, L.E., and G.G. Carmichael. 2001. Quality control of mRNA function.
Cell. 104:173–176.
Micklem, D.R. 1995. mRNA localisation during development. Dev. Biol. 172:
377–395.
Minshall, N., G. Thom, and N. Standart. 2001. A conserved role of a DEAD box
helicase in mRNA masking. RNA. 7:1728–1742.
Mitchell, P., and D. Tollervey. 2000. Musing on the structural organization of the
exosome complex. Nat. Struct. Biol. 7:843–846.
Mitchell, P., and D. Tollervey. 2003. An NMD pathway in yeast involving acceler-
ated deadenylation and exosome-mediated 3 →5  degradation. Mol. Cell.
11:1405–1413.
Miyawaki, A., and R.Y. Tsien. 2000. Monitoring protein conformations and inter-
actions by fluorescence resonance energy transfer between mutants of green
fluorescent protein. Methods Enzymol. 327:472–500.
Nathanson, L., T. Xia, and M.P. Deutscher. 2003. Nuclear protein synthesis: a re-
evaluation. RNA. 9:9–13.
Paddison, P.J., A.A. Caudy, E. Bernstein, G.J. Hannon, and D.S. Conklin. 2002.
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mam-
malian cells. Genes Dev. 16:948–958.
Pap, M., and G.M. Cooper. 2002. Role of translation initiation factor 2B in con-
trol of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen syn-
thase kinase 3beta signaling pathway. Mol. Cell. Biol. 22:578–586.
Patterson, G.H., D.W. Piston, and B.G. Barisas. 2000. Forster distances between
green fluorescent protein pairs. Anal. Biochem. 284:438–440.
Raijmakers, R., W.V. Egberts, W.J. van Venrooij, and G.J. Pruijn. 2003. The asso-
ciation of the human PM/Scl-75 autoantigen with the exosome is dependent
on a newly identified N terminus. J. Biol. Chem. 278:30698–30704.
Ross, J. 1995. mRNA stability in mammalian cells. Microbiol. Rev. 59:423–450.
Ross, J. 1997. A hypothesis to explain why translation inhibitors stabilize mRNAs
in mammalian cells: mRNA stability and mitosis. Bioessays. 19:527–529.
Salehi, Z., L. Geffers, C. Vilela, R. Birkenhager, M. Ptushkina, K. Berthelot, M.
Ferro, S. Gaskell, I. Hagan, B. Stapley, and J.E. McCarthy. 2002. A nuclear
protein in Schizosaccharomyces pombe with homology to the human tumour
suppressor Fhit has decapping activity. Mol. Microbiol. 46:49–62.
Salgado-Garrido, J., E. Bragado-Nilsson, S. Kandels-Lewis, and B. Séraphin. 1999.
Sm and Sm-like proteins assemble in two related complexes of deep evolu-
tionary origin. EMBO J. 18:3451–3462.
Sambrook, J., E.J. Fritsch, and T. Maniatis. 1989. Ligation of cohesive termini. In
Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY. 1.68–1.69.
Sheth, U., and R. Parker. 2003. Decapping and decay of messenger RNA occur in
cytoplasmic processing bodies. Science. 300:805–808.
Smillie, D.A., and J. Sommerville. 2002. RNA helicase p54 (DDX6) is a shuttling
protein involved in nuclear assembly of stored mRNP particles. J. Cell Sci.
115:395–407.
St Johnston, D. 1995. The intracellular localization of messenger RNAs. Cell. 81:
161–170.
Takahashi, S., Y. Araki, T. Sakuno, and T. Katada. 2003. Interaction between
Ski7p and Upf1p is required for nonsense-mediated 3 -to-5  mRNA decay
in yeast. EMBO J. 22:3951–3959.
Tharun, S., W. He, A.E. Mayes, P. Lennertz, J.D. Beggs, and R. Parker. 2000.
Yeast Sm-like proteins function in mRNA decapping and decay. Nature.
404:515–518.
van Dijk, E.L., J.S. Sussenbach, and P.E. Holthuizen. 2001. Kinetics and regula-
tion of site-specific endonucleolytic cleavage of human IGF-II mRNAs. Nu-
cleic Acids Res. 29:3477–3486.
van Dijk, E., N. Cougot, S. Meyer, S. Babajko, E. Wahle, and B. Séraphin. 2002.
Human Dcp2: a catalytically active mRNA decapping enzyme located in
specific cytoplasmic structures. EMBO J. 21:6915–6924.
van Dijk, E., H. Le Hir, and B. Séraphin. 2003. DcpS can act in the 5 -3  mRNA
decay pathway in addition to the 3 -5  pathway. Proc. Natl. Acad. Sci. USA.
100:12081–12086.
van Hoof, A., P.A. Frischmeyer, H.C. Dietz, and R. Parker. 2002. Exosome-medi-
ated recognition and degradation of mRNAs lacking a termination codon.
Science. 295:2262–2264.
Verveer, P.J., A.G. Harpur, and P.I.H. Bastiaens. 2002. Imaging protein interac-
tions by FRET microscopy. In Protein-Protein Interactions. E. Golemis, ed-
itor. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 181–
214.
Visa, N., E. Izaurralde, J. Ferreira, B. Daneholt, and I.W. Mattaj. 1996. A nuclear
cap-binding complex binds Balbiani ring pre-mRNA cotranscriptionally and
accompanies the ribonucleoprotein particle during nuclear export. J. Cell
Biol. 133:5–14.
Wang, Z., and M. Kiledjian. 2001. Functional link between the mammalian exo-
some and mRNA decapping. Cell. 107:751–762.
Wang, Z., X. Jiao, A. Carr-Schmid, and M. Kiledjian. 2002. The hDcp2 protein is
a mammalian mRNA decapping enzyme. Proc. Natl. Acad. Sci. USA. 99:
12663–12668.
Wouters, F.S., P.J. Verveer, and P.I. Bastiaens. 2001. Imaging biochemistry inside
cells. Trends Cell Biol. 11:203–211.